Macrolide Pharmaceuticals

It is becoming increasingly recognized that bacterial antibiotic resistance is outstripping the development of new antibiotic therapeutics, and some authorities even warn of a return to the pre-antibiotic era, where life-threatening infections cannot be successfully treated.

Learn More   Contact Us

New era in anti-infective technology

Macrolide technology solves this problem and enables the total synthesis of virtually any macrolide, so thousands of novel macrolide compounds can now be made and tested that were previously inaccessible.

The Opportunity

 

It is becoming increasingly recognized that bacterial antibiotic resistance is outstripping the development of new antibiotic therapeutics, and some authorities even warn of a return to the pre-antibiotic era, where life-threatening infections cannot be successfully treated. Prof. Myers and Dr. Lawrence Miller previously co-founded Tetraphase Pharmaceuticals (NASDAQ: TTPH), which is now commercializing…

Fast Track

 

The transformative new technology developed by Prof. Myers for the first time enables a practical, intrinsically scalable and readily diversifiable, total synthesis of macrolide structures from basic building blocks. The synthesis has been proven in the laboratory, and is already producing significant numbers of novel, fifth generation macrolide compounds for testing. In fact, nearly 140 completely novel macrolides …

Objective

 

The objective of Macrolide Pharmaceuticals Inc. is to develop new, fifth generation macrolide antibiotics active against a variety of organisms, especially gram-negative bacteria, and with both intravenous and oral availability. The Myers technology offers a unique opportunity to dramatically extend one of the most successful classes of antibiotics, renowned for safety and efficacy, and achieve this objective. …

Founding Team

Macrolide technology solves this problem and enables the total synthesis of virtually any macrolide, so thousands of novel macrolide compounds can now be made and tested that were previously inaccessible.

Lawrence G. Miller, M.D.

Lawrence G. Miller, M.D.

CEO

Dr. Miller is a highly experienced company founder and manager, working closely with 9 companies over the past 25 years, including HPR, Avicenna Systems, Serenex and PharMetrics. He was a co-founder of Tetraphase Pharmaceuticals with Prof. Myers. He was educated at Harvard and completed clinical training at the Massachusetts General Hospital.
Prof. Andrew G. Myers

Prof. Andrew G. Myers

Chief Scientist

Prof. Myer, Houghton Professor of Chemistry at Harvard University, is among the world’s leading synthetic chemists. He was a co-founder of Tetraphase Pharmaceuticals with Dr. Miller. He was educated at MIT and Harvard, and previously was a faculty member at Caltech.
Macrolide technology enables the total synthesis of virtually any macrolide, so thousands of novel macrolide compounds can be made and tested that were previously inaccessible.

~ Professor Andrew Myers

News & Insights

News, ideas and conversations with the Macrolide Pharmaceuticals team and other notables.

Building a Better Haystack

June 9, 2016-Selina Koch- A year after raising $22 million in a series A round, Macrolide Pharmaceuticals Inc. has disclosed details of how its antibiotic discovery platform is creating a library of compounds with greater structural diversity than was previously possible – starting with eight simple building blocks….

read more

The Drug Push – Fighting Drug Resistant Bacteria

Macrolide was featured this month in AAAS magazine Science article “The Drug Push – fighting drug resistant bacteria”.

As fears of drug resistant bacteria loom, governments try to coax companies back to the field.

Read the article below or download.

read more